IV tranexamic acid may not impact outcomes after tibial tubercle osteotomy
SAN FRANCISCO — Use of IV tranexamic acid during tibial tubercle osteotomy did not significantly impact blood loss or hemarthrosis, opioid consumption, postoperative pain or functional outcomes, according to results presented here.
Michael J. Alaia, MD, and colleagues categorized patients undergoing tibial tubercle osteotomy into groups to receive either 1 g of IV tranexamic acid preoperatively and 1 g just prior to letting down the tourniquet (experimental group) or not (control group). Researchers considered estimated blood loss and presence of hemarthrosis and aspiration of the affected knee as the primary outcomes, while postoperative pain and function were considered secondary outcomes. Researchers also collected VAS scores and opioid consumption in regard to morphine milligram equivalents.
Results showed no differences in the rate of hemarthrosis and in the amount of blood that was aspirated between the two groups, according to Alaia.
“More importantly, we found no significant wound complications that required reoperation,” Alaia said in his presentation at the Arthroscopy Association of North America Annual Meeting.
Alaia noted the two groups had similar VAS scores and opioid consumption from postoperative day 1 to postoperative week 6. He added the two groups had equal thigh circumference ratio and the same amount of quadriceps activation.
“In terms of functional outcomes, regarding straight leg raise and range of motion, again, everything was completely symmetric at all of our follow-up visits,” Alaia said.
Collapse
Blaeser AM, et al. Tranexamic acid has no effect on postoperative hemarthrosis or pain after tibial tubercle osteotomy. Presented at: Arthroscopy Association of North America Annual Meeting. May 19-21, 2022; San Francisco.
Read more about